Consensus Ardelyx, Inc.

Stocks

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-08 EDT			5-day change	1st Jan Change
3.770 ^USD	-0.26%		+0.27%	-35.33%

08-17	Ardelyx, Inc. Announces Resignation of Eric Foster from Chief Commercial Officer, Effective August 28, 2026	CI
08-07	Wedbush Adjusts Price Target on Ardelyx to $9 From $19, Maintains Outperform Rating	MT

Evolution of the Average Target: Ardelyx, Inc.

Evolution of the Target Price: Ardelyx, Inc.

Changes in Analyst Recommendations: Ardelyx, Inc.

7b17c0b04.iHE7OHFKRxUwSjw4RJenGdZ68vGNA15cAd0hi1iypaE.yiRscB4tKUNqFU0VJuTlRrseiri9O2gUb-176T3c4suwAnpSOxAWQ0I_cQ~f80b2e12312c622a5d70b96fcd3b3fc9

Analysts' recommendations: Ardelyx, Inc.

08-07	Wedbush Adjusts Price Target on Ardelyx to $9 From $19, Maintains Outperform Rating	MT
01-21	Wedbush Raises Price Target on Ardelyx to $19 From $16, Keeps Outperform Rating	MT
01-09	Piper Sandler Upgrades Ardelyx to Overweight From Neutral	MT
25-08-05	Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	MT
25-07-15	Wedbush Raises Price Target on Ardelyx to $13 From $11, Keeps Outperform Rating	MT
25-05-02	Ardelyx's Q1 Loss Widens; Shares Fall	MT
25-05-02	Raymond James Downgrades Ardelyx to Outperform From Strong Buy, Adjusts Price Target to $11 From $13	MT
25-03-04	BTIG Initiates Ardelyx at Buy With $14 Price Target	MT
24-11-11	HC Wainwright Downgrades Ardelyx to Neutral From Buy, Adjusts Price Target to $5.50 From $11.50	MT
24-07-03	HC Wainwright Adjusts Ardelyx's Price Target to $10 From $13, Keeps Buy Rating	MT
24-07-02	Piper Sandler Downgrades Ardelyx to Neutral From Overweight, Cuts Price Target to $7 From $15; Shares Plunge	MT
24-07-02	Wedbush Adjusts Ardelyx's Price Target to $11 From $15, Keeps Outperform Rating	MT
24-05-03	Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating	MT
24-04-17	Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	MT
24-04-05	Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target	MT
24-01-12	Wedbush Adjusts Price Target on Ardelyx to $13 From $9, Maintains Outperform Rating	MT
24-01-10	Citigroup Raises Price Target on Ardelyx to $14 From $9, Maintains Buy Rating	MT
24-01-09	Raymond James Adjusts Ardelyx's Price Target to $15 From $12, Keeps Strong Buy Rating	MT
23-12-18	Raymond James Initiates Ardelyx at Strong Buy Rating With $12 Price Target	MT
23-11-01	HC Wainwright Raises Price Target on Ardelyx to $11 From $9, Maintains Buy Rating	MT
23-10-18	Wedbush Raises Ardelyx's Price Target to $9 From $7, Maintains Outperform Rating	MT
23-09-07	HC Wainwright Initiates Coverage on Ardelyx at Buy, $9 Price Target	MT
23-08-25	Cantor Fitzgerald Upgrades Ardelyx to Overweight From Neutral, Adjusts Price Target to $10 From $5	MT
23-08-03	Ladenburg Thalmann Adjusts Price Target on Ardelyx to $8.50 From $7.50, Maintains Buy Rating	MT
23-04-17	Wedbush Lifts Ardelyx's Price Target to $7 From $6, Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARDELYX, INC.					+242.18%
	WUXI APPTEC CO., LTD.					+19.65%
	ARGENX SE					+16.26%
	INSMED INCORPORATED					+60.29%
	BIONTECH SE					+20.86%
	WUXI BIOLOGICS (CAYMAN) INC.					+17.06%
	GENMAB A/S					+13.34%
	PHARMAESSENTIA CORPORATION					-0.55%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.73%
	EXELIXIS, INC.					-6.91%
	Average					+40.89%
	Weighted average by Cap.					+20.70%